Clinical Trial

Generation of Reactive T Cells Based on Tumor Whole Cell Antigen Nanovaccines

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2025 (before its estimated July 10, 2026 completion). Its status may not reflect the trial's current state.
Summary
Tumor-reactive T cells are generated based on the tumor full antigen nanovaccine and the tumor-reactive T cells are reinjected for autologous therapy to provide the optimal treatment plan for clinical patients.
Trial Details
NCT Number NCT07239544
Lead Sponsor The First Affiliated Hospital of Soochow University
Conditions Lung Cancer (NSCLC)
Enrollment 50 participants
Start Date 2025-07-10
Primary Completion 2026-07-10 (estimated)
Study Completion 2026-07-10 (estimated)
Updated on ClinicalTrials.gov 2025-11-20